DRPSHP

Scientific Reference

GLOW Stack

Evidence profile: Component evidence only — this formulation has not itself been studied

GLOW is a single preparation containing three separately studied peptides: GHK-Cu, TB-500 and BPC-157. GHK-Cu is the copper(II) complex of glycyl-histidyl-lysine, a tripeptide originally isolated from human plasma. TB-500 is the seven-residue synthetic fragment Ac-LKKTETQ, copied from the actin-binding region of thymosin beta-4. BPC-157 is a 15-residue synthetic peptide derived from a protein described in gastric juice. Each has its own literature, largely in cell culture and animals. No published study has tested the three together, and there is nothing on how stable they are, or how they behave, when mixed.

Mechanism of Action

The blend has no mechanism of its own, so the only honest account is of the three parts, each on its own evidence. GHK holds copper(II) tightly, and fibroblast cultures have been used to look at collagen and glycosaminoglycan synthesis in response to the complex. Thymosin beta-4 binds monomeric actin and governs how much is available for filament building; TB-500 reproduces LKKTETQ, the short sequence at the centre of that binding region, though how far the fragment shares the binding is not well established. How BPC-157 works is unsettled, with rodent and cell studies looking at nitric oxide and VEGF receptor pathways. Whether the three influence each other has not been investigated.

Molecular Information

  • Type: Three-peptide blend

Published Research

  • RGN-259 neurotrophic keratopathy phase III

    0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial

    Sosne G et al. · International journal of molecular sciences · 2022 · Clinical · Evidence for TB-500 (Thymosin Beta-4)

    PMID 36613994 — View on PubMed

  • The effect of thymosin treatment of venous ulcers

    Guarnera G et al. · Annals of the New York Academy of Sciences · 2010 · Clinical · Evidence for TB-500 (Thymosin Beta-4)

    PMID 20536470 — View on PubMed

  • A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers

    Ruff D et al. · Annals of the New York Academy of Sciences · 2010 · Clinical · Evidence for TB-500 (Thymosin Beta-4)

    PMID 20536472 — View on PubMed

  • Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin

    Miller TR et al. · Archives of facial plastic surgery · 2006 · Clinical · Evidence for GHK-Cu

    PMID 16847171 — View on PubMed

  • A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers

    Bishop JB et al. · Journal of vascular surgery · 1992 · Clinical · Evidence for GHK-Cu

    PMID 1495150 — View on PubMed

  • Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

    Mayfield CK et al. · The American journal of sports medicine · 2026 · Review · Evidence for BPC-157

    PMID 41476424 — View on PubMed